A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide

Journal of Hematology & Oncology

Allen S Yang²  Kuolung Hu²  Bart Scott⁴  Carmen Matei⁶  Delong Liu⁸  Sunil Gandhi⁷  Richard A Larson³  Roger M Lyons¹  Eunice S Wang⁵ 

[1] Cancer Care Centers of South Texas/US Oncology, 4411 Medical Drive, Suite 100, San Antonio, TX, 78229, USA;Amgen Inc., One Amgen Center Drive, Thousand Oaks, California, 91320, USA;Comprehensive Cancer Center, University of Chicago, 5841 S. Maryland Avenue, MC-2115, Chicago, Illinois, 60637, USA;Fred Hutchinson Cancer Research Center, 1100 Fairview Ave. N, D1-100, Seattle, Washington, 98109, USA;Leukemia Service, Department of Medicine, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA;Rocky Mountain Cancer Centers/US Oncology, 3027 North Circle Drive, Colorado Springs, CO, 80909, USA;Cancer and Blood Disease Center, 421 N. Lecanto Highway, Lecanto, Florida, 34461, USA;Westchester Medical Center, Munger Pavilion 250, Valhalla, New York, 10595, USA

关键词: Myelodysplastic syndrome;    Thrombocytopenia;    Lenalidomide;    Romiplostim;   

Others  :  812696
DOI  :  10.1186/1756-8722-5-71

 received in 2012-11-02, accepted in 2012-11-18,  发布年份 2012

【 摘 要 】

Background

Lenalidomide treatment in myelodysplastic syndrome (MDS) may lead to thrombocytopenia and dose reductions/delays. This study evaluated the safety and tolerability of the thrombopoietin mimetic romiplostim and its effects on the incidence of clinically significant thrombocytopenic events (CSTEs) in lower risk MDS patients receiving lenalidomide.

Methods

Patients were assigned to weekly placebo (n = 12) or romiplostim 500 μg (n = 14) or 750 μg (n = 13) for four 28-day lenalidomide cycles.

Results

The treatment groups were generally similar with respect to baseline disease characteristics. Del(5q) abnormalities were noted in 1 (8%) patient in the placebo group, 3 (21%) in the romiplostim 500 μg group, and two (15%) in the 750 μg group. CSTEs were noted in 8 (67%) patients in the placebo group, 4 (29%) in the romiplostim 500 μg group, and 8 (62%) in the romiplostim 750 μg group. Throughout the study, median platelet counts trended lower in placebo-treated than in romiplostim-treated patients. Thrombocytopenia-related adjustments in lenalidomide occurred in 6 (50%) patients in the placebo group, 5 (36%) in the romiplostim 500 μg group, and 2 (15%) in the 750 μg group. Although the percentages of patients who received platelet transfusions were similar across treatment groups, there was a trend toward lower numbers of transfusions in both romiplostim groups during each treatment cycle. There were two serious treatment-related adverse events during the treatment period (cerebrovascular accident, placebo; worsening thrombocytopenia, romiplostim 500 μg). Two patients (romiplostim 500 and 750 μg, respectively) had an increase in bone marrow blasts to >20% during treatment, but had no post-treatment biopsy to confirm or exclude the diagnosis of progression to AML.

Conclusions

These data suggest that romiplostim administered to MDS patients during lenalidomide treatment may decrease the frequency of dose reductions/delays due to thrombocytopenia. Additional study is needed to confirm the results of this preliminary trial.

Trial registration

ClinicalTrials.gov NCT00418665

【 授权许可】

   
2012 Wang et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Tefferi A, Vardiman JW: Myelodysplastic syndromes. N Engl J Med 2009, 361(19):1872-1885.
• [2]Hofmann WK, Koeffler HP: Myelodysplastic syndrome. Annu Rev Med 2005, 56:1-16.
• [3]Dansey R: Myelodysplasia. Curr Opin Oncol 2000, 12(1):13-21.
• [4]Cogle CR, Craig BM, Rollison DE, List AF: Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: high number of uncaptured cases by cancer registries. Blood 2011, 117(26):7121-7125.
• [5]Goldberg SL, Chen E, Corral M, Guo A, Mody-Patel N, Pecora AL, Laouri M: Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries. J Clin Oncol 2010, 28(17):2847-2852.
• [6]Kantarjian H, Giles F, List A, Lyons R, Sekeres MA, Pierce S, Deuson R, Leveque J: The incidence and impact of thrombocytopenia in myelodysplastic syndromes. Cancer 2007, 109(9):1705-1714.
• [7]Neukirchen J, Blum S, Kuendgen A, Strupp C, Aivado M, Haas R, Aul C, Gattermann N, Germing U: Platelet counts and haemorrhagic diathesis in patients with myelodysplastic syndromes. Eur J Haematol 2009, 83(5):477-482.
• [8]Garcia-Manero G, Shan J, Faderl S, Cortes J, Ravandi F, Borthakur G, Wierda WG, Pierce S, Estey E, Liu J, et al.: A prognostic score for patients with lower risk myelodysplastic syndrome. Leukemia 2008, 22(3):538-543.
• [9]Jadersten M, Hellstrom-Lindberg E: Myelodysplastic syndromes: biology and treatment. J Intern Med 2009, 265(3):307-328.
• [10]Mohamedali A, Mufti GJ: Van-den Berghe's 5q- syndrome in 2008. Br J Haematol 2009, 144(2):157-168.
• [11]Haase D, Germing U, Schanz J, Pfeilstocker M, Nosslinger T, Hildebrandt B, Kundgen A, Lubbert M, Kunzmann R, Giagounidis AA, et al.: New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood 2007, 110(13):4385-4395.
• [12]REVLIMID(R): [http://www.revlimid.com/pdf/REVLIMID_PI.pdf] webcite(Lenalidomide) Capsules, for Oral Use [Prescribing Information]. CA: Celgene Corporation, San Diego; May 2012.
• [13]List A, Dewald G, Bennett J, Giagounidis A, Raza A, Feldman E, Powell B, Greenberg P, Thomas D, Stone R, et al.: Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006, 355(14):1456-1465.
• [14]List A, Kurtin S, Roe DJ, Buresh A, Mahadevan D, Fuchs D, Rimsza L, Heaton R, Knight R, Zeldis JB: Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 2005, 352(6):549-557.
• [15]Fenaux P, Giagounidis A, Selleslag D, Beyne-Rauzy O, Mufti G, Mittelman M, Muus P, Te Boekhorst P, Sanz G, Del Canizo C, et al.: A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q. Blood 2011, 118(14):3765-3776.
• [16]Sekeres MA, Maciejewski JP, Giagounidis AA, Wride K, Knight R, Raza A, List AF: Relationship of treatment-related cytopenias and response to lenalidomide in patients with lower-risk myelodysplastic syndromes. J Clin Oncol 2008, 26(36):5943-5949.
• [17]Wang B, Nichol JL, Sullivan JT: Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand. Clin Pharmacol Ther 2004, 76(6):628-638.
• [18]Nplate(R): [http://pi.amgen.com/united_states/nplate/nplate_pi_hcp_english.pdf] webcite(Romiplostim), for Subcutaneous Injection [Prescribing Information]. CA: Amgen Inc, Thousand Oaks; November 2012.
• [19]Kantarjian H, Fenaux P, Sekeres MA, Becker PS, Boruchov A, Bowen D, Hellstrom-Lindberg E, Larson RA, Lyons RM, Muus P, et al.: Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia. J Clin Oncol 2010, 28(3):437-444.
• [20]Sekeres MA, Kantarjian H, Fenaux P, Becker P, Boruchov A, Guerci-Bresler A, Hu K, Franklin J, Wang YM, Berger D: Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromes. Cancer 2011, 117(5):992-1000.
• [21]Fenaux P, Kantarjian H, Muus P, Lyons RM, Larson RA, Sekeres MA, Becker PS, Jia C, Yang AS: Update of an open-label extension study evaluating the long-term safety and efficacy of romiplostim in thrombocytopenic patients with myelodysplastic syndromes (MDS). Blood 2011, 118(21):2772. (ASH Annual Meeting Abstracts)
• [22]Giagounidis A, Mufti GJ, Kantarjian HM, Fenaux P, Sekeres MA, Szer J, Kuendgen A, Platzbecker U, Gaidano G, Jedrzejczak W, Hu K, Yang AS, Jun S: Treatment with the thrombopoietin (TPO)-receptor agonist romiplostim in thrombocytopenic patients (pts) with low or intermediate-1 (int-1) risk myelodysplastic syndrome (MDS): results of a randomized, double-blind, placebo(PBO)-controlled study. Blood 2011, 118(21):Abstract 117.
• [23]Greenberg PL, Garcia-Manero G, Moore M, Damon L, Roboz G, Hu K, Yang AS, Franklin J: A randomized controlled trial of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome (MDS) receiving decitabine. Leuk Lymphoma 2012. Nov 15 [Epub ahead of print].
• [24]Cheson BD, Bennett JM, Kantarjian H, Pinto A, Schiffer CA, Nimer SD, Lowenberg B, Beran M, de Witte TM, Stone RM, et al.: Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 2000, 96(12):3671-3674.
• [25]Kantarjian HM, Giles FJ, Greenberg PL, Paquette RL, Wang ES, Gabrilove JL, Garcia-Manero G, Hu K, Franklin JL, Berger DP: Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy. Blood 2010, 116(17):3163-3170.
• [26]Vardiman JW, Harris NL, Brunning RD: The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002, 100(7):2292-2302.
• [27]Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, et al.: International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997, 89(6):2079-2088.
• [28]Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD, Pinto A, Beran M, de Witte TM, Stone RM, et al.: Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006, 108(2):419-425.